Samuel Lee

Samuel Lee, MD, MBA, is a prominent leader in the biopharmaceutical and life sciences sectors, serving as Co-Founder, President, and Chief Business Officer at Eikonoklastes Therapeutics, Inc., since 2019, where the focus is on innovative treatments for neurodegenerative diseases. Additionally, Samuel is an Executive In Residence and Director at CincyTech USA, contributing to the development of high-performing life science companies and supporting various portfolio firms. As a Principal in Life Sciences at American Gene Technologies and an angel investor in multiple startups, including Vincere Biosciences and Swift Solar, Samuel actively invests in groundbreaking solutions across diverse fields. Educational credentials include a Doctor of Medicine from the University of Cincinnati, a Master’s in Public Health and Health Care Management from The Johns Hopkins University, and an MBA from Stanford University, complemented by a Bachelor of Arts in Biochemistry from Miami University.